Silvia Di Giacomo

Dr. Silvia Di Giacomo

Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
Antonella Di SottoAntonella Di Sotto
Antonella Di Sotto
Annabella VitaloneAnnabella Vitalone
Annabella Vitalone
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
Immunomodulators are agents able to affect the immune system, by boosting the immune defences to improve the body reaction against infectious or exogenous injuries, or suppressing the abnormal immune response occurring in immune disorders. Moreover, immunoadjuvants can support immune system acting on nonimmune targets, thus improving the immune response. The modulation of inflammatory pathways and microbiome can also contribute to control the immune function. Some plant-based nutraceuticals have been studied as possible immunomodulating agents due to their multiple and pleiotropic effects. Being usually more tolerable than pharmacological treatments, their adjuvant contribution is approached as a desirable nutraceutical strategy. In the present review, the up to date knowledge about the immunomodulating properties of polysaccharides, fatty acids and labdane diterpenes have been analyzed, in order to give scientific basic and clinical evidence to support their practical use. Since promising evidence in preclinical studies, limited and sometimes confusing results have been highlighted in clinical trials, likely due to low methodological quality and lacking standardization. More investigations of high quality and specificity are required to describe in depth the usefulness of these plant-derived nutraceuticals in the immune system modulation, for health promoting and disease preventing purposes.

17 September 2016 in Molecules
Verified
Journal Article
Open access
PDF file
GMGabriela Mazzanti
Gabriela Mazzanti
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
A growing body of in vitro and in vivo evidences shows a possible role of polyphenols in counteracting neurodegeneration: curcumin and resveratrol are attractive substances in this regard. In fact, epidemiological studies highlight a neuroprotective effect of turmeric (rhizome of Curcuma longa L.), the main source of curcumin. Moreover, the consumption of red wine, the main source of resveratrol, has been related to a lower risk of developing dementia. In this review, we analyzed the published clinical trials investigating curcumin and resveratrol in the prevention or treatment of cognitive disorders. The ongoing studies were also described, in order to give an overview of the current search on this topic. The results of published trials (five for curcumin, six for resveratrol) are disappointing and do not allow to draw conclusions about the therapeutic or neuroprotective potential of curcumin and resveratrol. These compounds, being capable of interfering with several processes implicated in the early stages of dementia, could be useful in preventing or in slowing down the pathology. To this aim, an early diagnosis using peripheral biomarkers becomes necessary. Furthermore, the potential preventive activity of curcumin and resveratrol should be evaluated in long-term exposure clinical trials, using preparations with high bioavailability and that are well standardized.

1 April 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
Jose MarinJose Marin
Jose Marin
ELElisa Lozano
Elisa Lozano
EAElisa Herraez Aguilar
Elisa Herraez Aguilar
MAMaitane Asensio
Maitane Asensio
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
RMRocio I.R. Macias
Rocio I.R. Macias

1 April 2016 in European Polymer Journal
Verified
Journal Article
Closed access
SPSettimio Pacelli
Settimio Pacelli
PPPatrizia Paolicelli
Patrizia Paolicelli
GMGiuseppe Moretti
Giuseppe Moretti
SPStefania Petralito
Stefania Petralito
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
MCMaria Antonietta Casadei
Maria Antonietta Casadei

8 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
EPEster Percaccio
Ester Percaccio
MGMarco Gullì
Marco Gullì
ARAdele Romano
Adele Romano
Annabella VitaloneAnnabella Vitalone
Annabella Vitalone
Antonella Di SottoAntonella Di Sotto
Antonella Di Sotto
Alzheimer’s disease (AD) is a progressive degenerative disorder of the central nervous system, characterized by neuroinflammation, neurotransmitter deficits, and neurodegeneration, which finally leads to neuronal death. Emerging evidence highlighted that hyperglycemia and brain insulin resistance represent risk factors for AD development, thus suggesting the existence of an additional AD form, associated with glucose metabolism impairment, named type 3 diabetes. Owing to the limited pharmacological options, novel strategies, especially dietary approaches based on the consumption of polyphenols, have been addressed to prevent or, at least, slow down AD progression. Among polyphenols, ferulic acid is a hydroxycinnamic acid derivative, widely distributed in nature, especially in cereal bran and fruits, and known to be endowed with many bioactivities, especially antioxidant, anti-inflammatory and antidiabetic, thus suggesting it could be exploited as a possible novel neuroprotective strategy. Considering the importance of ferulic acid as a bioactive molecule and its widespread distribution in foods and medicinal plants, the aim of the present narrative review is to provide an overview on the existing preclinical and clinical evidence about the neuroprotective properties and mechanisms of action of ferulic acid, also focusing on its ability to modulate glucose homeostasis, in order to support a further therapeutic interest for AD and type 3 diabetes.

18 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Antonella Di SottoAntonella Di Sotto
Antonella Di Sotto
RMRomina Mancinelli
Romina Mancinelli
MGMarco Gullì
Marco Gullì
Margherita EufemiMargherita Eufemi
Margherita Eufemi
CMCaterina Loredana Mammola
Caterina Loredana Mammola
Silvia Di GiacomoSilvia Di Giacomo
Silvia Di Giacomo
Chemoprevention is referred to as a strategy to inhibit, suppress, or reverse tumor development and progression in healthy people along with high-risk subjects and oncologic patients through using pharmacological or natural substances. Numerous phytochemicals have been widely described in the literature to possess chemopreventive properties, although their clinical usefulness remains to be defined. Among them, caryophyllane sesquiterpenes are natural compounds widely occurring in nature kingdoms, especially in plants, fungi, and marine environments. Several structures, characterized by a common caryophyllane skeleton with further rearrangements, have been identified, but those isolated from plant essential oils, including β-caryophyllene, β-caryophyllene oxide, α-humulene, and isocaryophyllene, have attracted the greatest pharmacological attention. Emerging evidence has outlined a complex polypharmacological profile of caryophyllane sesquiterpenes characterized by blocking, suppressing, chemosensitizing, and cytoprotective properties, which suggests a possible usefulness of these natural substances in cancer chemoprevention for both preventive and adjuvant purposes. In the present review, the scientific knowledge about the chemopreventive properties of caryophyllane sesquiterpenes and the mechanisms involved have been collected and discussed; moreover, possible structure–activity relationships have been highlighted. Although further high-quality studies are required, the promising preclinical findings and the safe pharmacological profile encourage further studies to define a clinical usefulness of caryophyllane sesquiterpenes in primary, secondary, or tertiary chemoprevention.